Continued follow-up of the phase 3 IMpower110 trial (NCT02409342) indicated that clinically meaningful survival and response benefit was maintained with frontline atezolizumab (Tecentriq) versus chemotherapy in patients with PD-L1–high, wild-type (WT) nonsquamous or squamous non–small cell lung cancer (NSCLC). Findings from the updated analysis that included a review of overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and duration of response (DOR) end points were presented during the 2020 World Conference on Lung Cancer Singapore.1
With a median follow up of 31.3 months, the median OS was 20.2 months with atezolizumab (n = 107) versus 14.7 months with chemotherapy (n = 98) in the high PD-L1 expression WT group. The 6-month OS rate was 76.5% versus 70.4%, respectively. The 12-month OS rate was 66.1% versus 52.3%, respectively (HR, 0.76; 95% CI,…
